HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 269 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $16,808 | +71.3% | 440 | +61.8% | 0.00% | – |
Q2 2023 | $9,811 | +94.6% | 272 | +106.1% | 0.00% | – |
Q1 2023 | $5,041 | -42.8% | 132 | -14.8% | 0.00% | – |
Q4 2022 | $8,820 | -19.8% | 155 | -44.2% | 0.00% | -100.0% |
Q3 2022 | $11,000 | +22.2% | 278 | +42.6% | 0.00% | – |
Q2 2022 | $9,000 | +50.0% | 195 | +25.0% | 0.00% | – |
Q1 2022 | $6,000 | 0.0% | 156 | +12.2% | 0.00% | – |
Q4 2021 | $6,000 | -57.1% | 139 | -59.9% | 0.00% | -100.0% |
Q3 2021 | $14,000 | +250.0% | 347 | +273.1% | 0.00% | – |
Q2 2021 | $4,000 | -33.3% | 93 | -38.8% | 0.00% | – |
Q1 2021 | $6,000 | +50.0% | 152 | +63.4% | 0.00% | – |
Q4 2020 | $4,000 | -42.9% | 93 | -65.3% | 0.00% | – |
Q3 2020 | $7,000 | 0.0% | 268 | 0.0% | 0.00% | – |
Q2 2020 | $7,000 | +133.3% | 268 | +45.7% | 0.00% | – |
Q1 2020 | $3,000 | 0.0% | 184 | +5.1% | 0.00% | – |
Q4 2019 | $3,000 | 0.0% | 175 | 0.0% | 0.00% | – |
Q3 2019 | $3,000 | 0.0% | 175 | 0.0% | 0.00% | – |
Q2 2019 | $3,000 | – | 175 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |